Key facts
- Tenvie’s last known valuation is $336.0M (Dec 2024).
- It has raised $200.0M; the latest was Later Stage VC ($200.0M) in Dec 2024.
- Notable investors include F-Prime Capital, ARCH Venture Partners, Mubadala Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Tenvie
- ·The full record, as it builds
Funding rounds
No funding rounds for Tenvie are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tenvie
Operator of a pharmaceutical research and development platform intended to discover and develop small molecule therapeutics for neurological, ardiometabolic, and ophthalmic diseases. The company's platform advances a differentiated pipeline of precisely engineered small molecule candidates that are designed to be either highly CNS-penetrant or peripherally restricted, targeting key disease drivers by resolving inflammation, rescuing metabolic dysfunction, and restoring lysosomal function, enabling healthcare providers and patients to access more targeted and potentially disease-modifying treatment options.
- Sector
- Healthcare
- HQ
- Brisbane, CA, United States
- Founded
- 2012
- Employees
- 32
- Website
- tenvie.com/
- Ownership
- Privately Held (backing)
Tenvie doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tenvie shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tenvie in its N-PORT filings yet. We sweep new filings monthly.